Cure My Disease

Don't miss your cure!

 Log in / Sign up

A brainstem dose limit might spare brain tumor patients from radiation nausea

NCT ID NCT06506578

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This study looks at whether the amount of radiation reaching a small brainstem region, the dorsal vagal complex, is linked to nausea in people receiving radiation for benign brain tumors. Researchers will track nausea scores and radiation doses in 100 adults. The goal is to find a dose threshold that could guide future treatment planning and reduce nausea.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiation therapy to the brain
What this could lead to
If a safe dose limit for the dorsal vagal complex is found, doctors could adjust radiation plans to reduce nausea for brain tumor patients.
What could go wrong
This is an observational study, so it won't prove that lowering the dose prevents nausea. The link may be weaker than expected, and other factors could influence results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

May 2022

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients irradiated with conventional fractionation (1,8-2Gy/fraction) for benign brain tumor

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * More than 18 years old * With benign brain tumor * Irradiated with conventional fractionation (1,8-2Gy/fraction) Exclusion Criteria: * History of brain radiation * History of head and neck radiation * Demencia * Concurrent chemotherapy * Nausea at the time of inclusion * Anti-nausea treatment : corticosteroids, metoclopramide, setrons, other

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Benign brain tumor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign neoplasm of brain brain cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Benign brain tumor

Contacts and locations

Locations

  • CHU de Bordeaux, Service de Radiothérapie

    Bordeaux, France

  • Hospices Civils de Lyon, Service d'Oncologie Radiothérapie - Hôpital Neurologique

    Lyon, France

  • Institut de cancérologie Strasbourg Europe (ICANS), Service d'Oncologie Radiothérapie

    Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.